Gaucher Disease
New Gaucher disease research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), real-world studies helped clarify how Gaucher treatments are used and tracked (ERT durability, infusion spacing, eliglustat markers), while gaps in diagnosis and monitoring were still reported. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Long-term ERT outcomes. Long follow-up and registry data sharpened real-world ERT expectations.
- Eliglustat in practice. Multiple small real-world reports linked eliglustat to marker drops.
- Pain, fatigue, daily life. Patient-reported burden was quantified alongside clinical measures.
- Beyond routine labs. More sensitive tests highlighted risks not captured by counts alone.
- Diagnosis delays and mix-ups. Surveys and screening programs quantified delays and mislabeling.
New
September 2026
- Platelet release. A platelet release problem often persisted, even with normal counts.
- Severity prediction. Genetics alone did not reliably predict neuronopathic disease severity.
- Brain support. In mice, MA-5 improved function without lowering brain storage.
August 2026
- Similar disease labeling. Some people referred for Gaucher testing had ASMD instead.
- Limits on confirmation. Without enzyme or genetic testing, diagnosis may remain uncertain.
- Eliglustat in children. A report on eliglustat in children was published, but its results were not available to us.
July 2026
- Long-term ERT effects. ERT gains often appeared early and lasted 10 to 15 years.
- ERT in pregnancy. One case reported ERT use in pregnancy without complications.
- COVID-19 hospitalization. After adjustment, Gaucher was not clearly linked to higher risk.
- Enzyme-boosting research. Early lab and animal studies raised enzyme signals, with safety concerns.
June 2026
- Enzyme replacement. Velaglucerase alfa was linked to better blood counts and smaller organs.
- MGUS risk signal. More years on therapy were linked to fewer new MGUS diagnoses.
- Pain and fatigue. Pain and fatigue were tied to worse quality of life.
May 2026
- Eliglustat follow-up. In a small report, adults taking eliglustat had Gaucher-related lab markers and liver/spleen size change in the expected direction.
- Lyso-Gb1 without treatment. In an untreated period, lyso-Gb1 often stayed stable but increased in a substantial minority, sometimes without earlier changes in routine blood counts.
- Parkinson risk with age. Registry data in type 1 Gaucher disease linked older age with a higher reported frequency of Parkinson disease, with differences across some GBA1 genetic categories.
April 2026
- Bone marrow scores. In adults on enzyme replacement therapy, marrow-related bone scores improved over time.
- Heart strain measure. A sensitive heart ultrasound strain measure was linked to later worsening on a Gaucher severity score in a small study.
- Symptoms over time. Over multi-year follow-up, subtle movement signs and some non-motor symptoms increased gradually.
March 2026
- Eliglustat blood markers. In Gaucher disease type 1, eliglustat was linked with lower Gaucher-related blood markers.
- Eliglustat side effects. Reported eliglustat side effects were usually mild, most often involving stomach or skin symptoms.
- Ambroxol add-on symptoms. In Gaucher disease type 3, adding ambroxol to enzyme therapy was linked with improvement in some neurologic symptoms in some people.
- Enzyme test variation. In healthy adults, “normal” glucocerebrosidase enzyme activity varied widely and differed by age and sex.
February 2026
- Longer infusion intervals. In registry data, some clinically stable people with Gaucher type 1 had similar outcomes when enzyme infusions were spaced farther apart, but this remains a real‑world question rather than a settled standard.
- Pregnancy registry findings. In a pregnancy registry of imiglucerase-treated Gaucher type 1, most pregnancies ended in live births and no stillbirths were reported in that dataset, adding context but not a definitive risk estimate.
- Diagnosis delays and screening limits. Surveys often found diagnosis delays of more than a year, and dried blood spot screening programs identified cases but sometimes ran into sample quality problems and incomplete follow‑up confirmation.
January 2026
- Liver and spleen stiffness. In a small study, adults with type 1 Gaucher disease on enzyme therapy still had higher liver and spleen stiffness than matched controls, suggesting follow-up may need to look beyond organ size.
- Metabolic changes after therapy. In the same treated adult group, some Gaucher-related measures improved while body weight and metabolic syndrome became more common, so liver findings may reflect both Gaucher and general metabolism.
- Lab methods affect enzyme results. In patient-derived cells, lab conditions changed measured enzyme activity, which can make results differ by testing method rather than by disease alone.
- Research models of nerve disease. A single severe childhood case and a fruit fly model showed neurologic decline despite improvements in other measures, but these examples may not reflect what happens for most people.
Get the monthly update by email
Subscribe here to receive an email when a new monthly Gaucher disease update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).